News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Velcera Announces Results From Two Canine Allergy Studies


1/30/2008 9:51:46 AM

YARDLEY, PA--(Marketwire - January 29, 2008) - Velcera, Inc. (OTCBB: VLCR), a specialty pharmaceutical company focused on pet health, announced today the results of two studies on Promistâ„¢-VEL502 as a treatment for the clinical signs of canine allergy. Canine allergy is one of the most common complaints of dog owners and manifests itself in the form of a skin irritation which causes the animal to scratch. Promistâ„¢-VEL502 is Velcera's second product in development based on its patented Promist drug delivery system, which provides a metered dose liquid mist inside the oral cavity for systemic absorption and avoids the need for pets to swallow tablets or liquids.

Read at BioSpace.com


comments powered by Disqus
Velcera
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES